Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SARS CoV 2 main protease inhibitors - Nxera Pharma

Next Previous
Search
Drug Profile

Research programme: SARS CoV 2 main protease inhibitors - Nxera Pharma

Alternative Names: 3CLPro protease inhibitors - Nxera Pharma; Coronavirus Nsp5 protease inhibitors - Nxera Pharma; inhibitors of the SARS-CoV-2 MPro protease - Nxera Pharma; MPro protease inhibitors - Nxera Pharma; SARS-CoV-2 main protease inhibitors - Nxera Pharma; SARS-CoV-2 MPro - Nxera Pharma

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sosei Heptares
  • Developer Nxera Pharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in Japan (PO)
  • 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
  • 14 Apr 2020 SARS-CoV-2 protease inhibitors - Sosei Heptares is available for licensing as of 14 Apr 2020. https://soseiheptares.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top